Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Sponsor: Novo Nordisk A/S
Summary
In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and semaglutide. The purpose is to examine whether cagrilintide can reduce the decline in bone mass associated to weight loss. Participants will either get cagrilintide, semaglutide, CagriSema (cagrilintide combined with semaglutide), or placebo. Which treatment participants get is decided by chance. Semaglutide is already approved for the treatment of overweight and obesity and can be prescribed by doctors. Cagrilintide and CagriSema are new medications currently under development for weight management. The study will last for about 79 weeks.
Official title: The Role of the Amylin Analogue Cagrilintide in Bone Metabolism During Weight Loss in Postmenopausal Women With Obesity
Key Details
Gender
FEMALE
Age Range
50 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
144
Start Date
2025-06-12
Completion Date
2028-05-03
Last Updated
2025-07-25
Healthy Volunteers
No
Conditions
Interventions
Cagrilintide
Participants will receive once-weekly cagrilintide subcutaneously.
Semaglutide
Participants will receive once-weekly semaglutide subcutaneously.
Placebo cagrilintide
Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.
Placebo semaglutide
Participants will receive once-weekly placebo matched to semaglutide subcutaneously.
Locations (1)
Steno Diabetes Center Copenhagen
Herlev, Denmark